CEST in Low-grade Glioma Study (NCT05996653)
A Multi-institutional Observational Study of CEST Imaging in Low-grade Glioma
🩺 Plain-English Summary (8th-Grade Level)
Low grade gliomas (LGGs) are malignant, infiltrative and incurable brain tumours that typically present in the younger population. This project proposes to use non-contrast metabolic "Saturation Transfer" (ST)-MRI to evaluate LGG tumour progression and aims to predict early changes in LGG. Early identification of LGG patients whose tumours will progress will permit early interventions. ST-MRI does not involve any intravenous injection of contrast and which acquires metabolic information not seen by standard MRI.
Who can join: Review the eligibility criteria below.
Location: Sunnybrook Health Sciences Centre — Toronto, Ontario
Age range: 12 Years
🧪 Interventions in This Study
- Saturation Transfer (ST)-MRI (DIAGNOSTIC_TEST)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- Sunnybrook Health Sciences Centre — Toronto, Ontario
- St. Michael's Hospital — Toronto, Ontario
📞 Contact the Study Coordinator
Phone: (416) 480-6100
Email: MaryJane.LimFat@sunnybrook.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Low-grade Glioma
- Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway. — Calgary, Alberta
- DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) — Birmingham, Alabama
- Niraparib In Recurrent IDH 1/2 Gliomas — Boston, Massachusetts
- SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma — Memphis, Tennessee
- Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas — Toronto, Ontario
Explore by condition: All Low-grade Glioma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.